Therapeutic use of allogenic human bone marrow-derived NSCs transfected with interferon-β (IFN-β) diminishes tumor growth, decreases metastasis, and increases longevity via AKT and ERK1/2 phosphorylation in the tumor cells (Bao et al., 2012; Hagenhoff et al., 2016; Romero-Trejo et al., 2021). The gene discussed is AKT1; the disease is neoplasm.